Pharma companies use a variety of means to become familiar with emerging candidates and technologies, including partnership and corporate venture investment. Only very rarely do they go on to seal the deal by acquiring their own partner or investment, demonstrating a vast preference for acquiring other companies’ partners and investments ([A#2012900190]).
Algeta ASA proved an exception to the rule, when it disclosed on Dec. 19 that its board recommended shareholders...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?